Literature DB >> 23154165

C-terminal turn stability determines assembly differences between Aβ40 and Aβ42.

Robin Roychaudhuri1, Mingfeng Yang, Atul Deshpande, Gregory M Cole, Sally Frautschy, Aleksey Lomakin, George B Benedek, David B Teplow.   

Abstract

Oligomerization of the amyloid β-protein (Aβ) is a seminal event in Alzheimer's disease. Aβ42, which is only two amino acids longer than Aβ40, is particularly pathogenic. Why this is so has not been elucidated fully. We report here results of computational and experimental studies revealing a C-terminal turn at Val36-Gly37 in Aβ42 that is not present in Aβ40. The dihedral angles of residues 36 and 37 in an Ile31-Ala42 peptide were consistent with β-turns, and a β-hairpin-like structure was indeed observed that was stabilized by hydrogen bonds and by hydrophobic interactions between residues 31-35 and residues 38-42. In contrast, Aβ(31-40) mainly existed as a statistical coil. To study the system experimentally, we chemically synthesized Aβ peptides containing amino acid substitutions designed to stabilize or destabilize the hairpin. The triple substitution Gly33Val-Val36Pro-Gly38Val ("VPV") facilitated Aβ42 hexamer and nonamer formation, while inhibiting formation of classical amyloid-type fibrils. These assemblies were as toxic as were assemblies from wild-type Aβ42. When substituted into Aβ40, the VPV substitution caused the peptide to oligomerize similarly to Aβ42. The modified Aβ40 was significantly more toxic than Aβ40. The double substitution d-Pro36-l-Pro37 abolished hexamer and dodecamer formation by Aβ42 and produced an oligomer size distribution similar to that of Aβ40. Our data suggest that the Val36-Gly37 turn could be the sine qua non of Aβ42. If true, this structure would be an exceptionally important therapeutic target.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154165      PMCID: PMC3540122          DOI: 10.1016/j.jmb.2012.11.006

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  60 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data.

Authors:  Lee Whitmore; B A Wallace
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

3.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

4.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

5.  Structure of the 21-30 fragment of amyloid beta-protein.

Authors:  Andrij Baumketner; Summer L Bernstein; Thomas Wyttenbach; Noel D Lazo; David B Teplow; Michael T Bowers; Joan-Emma Shea
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

6.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 7.  Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.

Authors:  T E Golde; C B Eckman; S G Younkin
Journal:  Biochim Biophys Acta       Date:  2000-07-26

8.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.

Authors:  Summer L Bernstein; Nicholas F Dupuis; Noel D Lazo; Thomas Wyttenbach; Margaret M Condron; Gal Bitan; David B Teplow; Joan-Emma Shea; Brandon T Ruotolo; Carol V Robinson; Michael T Bowers
Journal:  Nat Chem       Date:  2009-07       Impact factor: 24.427

9.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

10.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

View more
  34 in total

1.  Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity.

Authors:  Robin Roychaudhuri; Xueyun Zheng; Aleksey Lomakin; Panchanan Maiti; Margaret M Condron; George B Benedek; Gal Bitan; Michael T Bowers; David B Teplow
Journal:  ACS Chem Neurosci       Date:  2015-10-19       Impact factor: 4.418

2.  Peptide dimer structure in an Aβ(1-42) fibril visualized with cryo-EM.

Authors:  Matthias Schmidt; Alexis Rohou; Keren Lasker; Jay K Yadav; Cordelia Schiene-Fischer; Marcus Fändrich; Nikolaus Grigorieff
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

3.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

4.  Familial Alzheimer's disease Osaka mutant (ΔE22) β-barrels suggest an explanation for the different Aβ1-40/42 preferred conformational states observed by experiment.

Authors:  Hyunbum Jang; Fernando Teran Arce; Srinivasan Ramachandran; Bruce L Kagan; Ratnesh Lal; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2013-09-13       Impact factor: 2.991

5.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

Review 6.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

7.  Conformational Ensembles of the Wild-Type and S8C Aβ1-42 Dimers.

Authors:  Viet Hoang Man; Phuong H Nguyen; Philippe Derreumaux
Journal:  J Phys Chem B       Date:  2017-03-10       Impact factor: 2.991

8.  Impact of sequence on the molecular assembly of short amyloid peptides.

Authors:  Victoria A Wagoner; Mookyung Cheon; Iksoo Chang; Carol K Hall
Journal:  Proteins       Date:  2014-02-18

Review 9.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

10.  Modulation of Amyloid-β42 Conformation by Small Molecules Through Nonspecific Binding.

Authors:  Chungwen Liang; Sergey N Savinov; Jasna Fejzo; Stephen J Eyles; Jianhan Chen
Journal:  J Chem Theory Comput       Date:  2019-09-04       Impact factor: 6.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.